about
Novel serial positive enrichment technology enables clinical multiparameter cell sortingEnhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosisHigh contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsReprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesityPeriplasmic chaperones used to enhance functional secretion of proteins in E. coli.Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-Deficient Lep(ob/ob) Mice.PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.The periplasmic E. coli chaperone Skp is a trimer in solution: biophysical and preliminary crystallographic characterization.Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.A system for concomitant overexpression of four periplasmic folding catalysts to improve secretory protein production in Escherichia coli.PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo EfficacyIntravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats
P50
Q28730418-6F0916E9-BC42-4172-B52D-B4FDC962B949Q34355672-1B903873-576D-4103-AC7F-B9811B92C06EQ36211450-C1473CAB-8EF1-4D41-8D76-5DA9DC0710DBQ37025675-A50465E5-05E5-4415-91D2-7F81154F87DDQ37278847-C99F1FA8-277D-4E7E-9CF9-43171FBFA4BDQ37815073-2A7CA9DB-9EED-479C-AD19-8114E6D5C531Q38295797-7166F5BF-E654-49F8-A5C2-7746A577808FQ39419306-14F501AB-A95B-446E-A8A4-86F6D3223002Q40459012-A3D9AB64-8173-4C9F-BF13-97E58CDE823AQ47723207-34171DD8-AC20-4A06-9FB0-5F0C9C4BE71DQ50801472-6216DB55-3471-46E5-BF98-CFC538D12CC5Q50969349-662E2633-A65F-4032-A07C-226BAA03CAAAQ51356106-0F3F68C6-2B95-4BCB-B492-F9A2FB584B8DQ54413518-320BF3BB-76C6-4654-8226-E89E2F4129B8Q54464752-29D7FEC1-BD20-47BF-BC27-5CD8A346BE80Q57260217-1AACBCE8-C8B0-43A3-8DA7-069E454516DEQ57260228-4FEDC145-4757-494C-84D9-A65F6CC9FAB3
P50
name
Martin Schlapschy
@en
Martin Schlapschy
@nl
type
label
Martin Schlapschy
@en
Martin Schlapschy
@nl
prefLabel
Martin Schlapschy
@en
Martin Schlapschy
@nl